objective To evaluate price, availability and affordability of insulin products in Shaanxi Province, western China.
Introduction
Insulin, a kind of human hormone playing an important role in the anabolic process, is essential for treating some diabetes mellitus patients. Injectable insulin is necessary for type 1 diabetes mellitus (T1DM) and some type 2 diabetes mellitus (T2DM) that cannot be controlled by oral medicine only [1] . Before the first extraction and purification of insulin in 1921 [2] , children with T1DM had to endure constant starvation until the end of their life because that was the only way to control blood glucose [3, 4] . With the introduction of insulin injections, the life expectancy of patients with T1DM has been extended. In the USA, the average life expectancy of children with T1DM is 4-6 years shorter than that of healthy people [5] . Besides, there is a significant shift in major consumers of insulin from T1DM patients to T2DM patients [6] [7] [8] [9] [10] . More and more T2DM patients, especially the elderly, benefit from using insulin products to avoid or control severe complications.
Although insulin is a life-saving medicine for many patients, unfortunately it remains inaccessible to those who are in greatest need. Even in developed countries such as the USA and the UK, access to insulin is suboptimal due to its high cost [11, 12] , which may result in insufficient treatment, serious complications like amputations, and even premature death.
China bears the heaviest burden of diabetes, with an estimated 113.9 million diabetes mellitus patients accounting for 11.6% of the adult population [13] . Another study [14] found an overall diabetes prevalence of 9.7% and of prediabetes of 15.5%. A recent survey estimated the prevalence of T1DM in China at about 1.01 incidence per 100 000 person's yearly [15] . Although the incidence of T1DM in China is lower than in some European countries, the sheer number of T1DM patients who need insulin is huge and keeps increasing [15] .
While the burden of diabetes in China is gigantic and the need for insulin is urgent, accessing insulin products is not easy for insulin-dependent patients due to high cost and low availability. Yang et al. found in 2010 [14] that only 25.8% of diabetes patients in China received treatment. Very few studies had assessed access to insulin before, except one in Hubei Province [16] , which revealed that its cost is very high in all sectors and availability is very poor except in tertiary public hospitals.
Since there are no such studies focusing on insulin access in western China, where the economic level is low and the incidence of diabetes is high [13] [14] [15] , this study measured prices, availability and affordability of insulin and some oral anti-diabetes medicines as comparators in Shaanxi Province, western China. We also investigated insulin price components (markups etc.) along the pharmaceutical supply chain.
Methods

Study setting
Shaanxi Province in western China has a population of 38 million and a high burden of diabetes. The annual mortality rate of diabetes (per 100 000 people) in Shaanxi is 8.4, which has increased by 28.3% since 1990 [17] . T1DM incidence in Shaanxi was estimated at 0.9 per 100 000 persons yearly and the highest incidence is in the age group 0-14 years [15] .
Insulin and most oral anti-diabetic medicines are prescription medicines in China. Although a very high percentage of the population is covered by basic health insurance in China, patients have to pay a high proportion of outpatient costs out-of-pocket. Urban employees pay more than 30% of all outpatient cost out-of-pocket; urban and rural residents have to bear more of the outpatient cost than employees, given that basic health insurance coverage focuses on inpatient costs [18, 19] .
Design
We conducted a field survey in Shaanxi Province from April 2016 to May 2016, using a simplified and adapted WHO/Health Action International (HAI) method [20] , to obtain the availability and patient prices of insulin products and five oral anti-diabetic medicines in public and private sectors. Additionally, as a case study, we investigated the price components of eight selected insulin products by tracing the supply chain.
We selected three districts in Shaanxi with different economic development levels: high-income, middleincome and low-income. The provincial city Xi'an was selected as high-income district, Xianyang as middleincome and Shangluo as low-income. The biggest public hospital and biggest private clinic in each district were selected for data collection, due to their ability to provide comprehensive care and various medicines for diabetes mellitus patients. In each district, five private retail pharmacies within 5 km of the selected public hospital were chosen to collect data. Private retail pharmacies were chosen by convenience sampling centering around the selected biggest public hospital. However, given that there is no large general private hospital in Xianyang and Shangluo, we chose a secondary public hospital as complement in these two districts. Thus, five public hospitals and 16 private retail pharmacies were included in this study (Table 1) .
Data collection
Trained data collectors (Z. Li and three undergraduate students) went to all 21 outlets to collect data using a specially designed form. Appointments with hospitals were made in advance, but not appointments with retail pharmacies. At the end of every day during the survey, the area supervisor checked the data collected.
Data collected included: insulin type, brand name, strength (number of International Units (IU) per millilitre), dosage form (presentation of insulin, such as vial, cartridge or pen), manufacturer and patient price of all insulin products. In addition, data were collected on four oral anti-diabetic medicines (metformin 500/250 mg, gliclazide 80/30 mg, acarbose 50 mg, and glimepiride 2 mg) as comparisons with insulin. For these four medicines, brand name, pack size and prices of both the original brands (OBs) and the lowest-priced generics (LPGs) were recorded in each outlet.
After the survey of insulin price and availability, we investigated insulin price components, taking the supply chain in Shaanxi as a case study. Eight insulin products were included in this price components study, of which 
Data analysis
Availability. According to the WHO/HAI Method Manual [20] , availability of individual medicine represents the percentage (%) of outlets in which the medicine was found on the day of data collection. In this study, insulin products were categorised into subtypes considering the therapeutic characteristics and duration of action: prandial insulin (short-acting and rapid-acting), basal insulin (intermediate-acting and long-acting), and premixed insulin. Availability was reported in each subtype. We compared availability of insulin products and oral antidiabetic medicines between public and private sector using descriptive statistics. The WHO report [21] classifies availability as follows: <30% -very low; 30-49% -low; 50-80% -fairly high; >80% -high.
Price. Price was measured by median price ratio (MPR) according to WHO/HAI Method, which is the ratio of median price of individual medicine collected during the survey to the international reference price (IPR). Recommended by HAI, the most commonly used reference price is the medicine price from Management Sciences for Health (MSH) [22] . However, as MSH lacks information on insulin, we resorted to other sources. Liu et al. [16] used the insulin price from the Australia Pharmaceutical Benefit Scheme (PBS) as the international reference price in their study evaluating insulin availability in Hubei, China. The PBS price could be viewed as patient price because it represents the reimbursement price from the Australian government [23] . In this study, we also adopted the PBS price as the international reference price. For oral anti-diabetic medicines, we adopted the newest MSH price as international reference price. Prices from PBS and MSH were transferred to the base year 2016 by consumer price index (CPI) [24] , and all prices were converted to US dollars using the exchange rate of the first day of this survey. It is worth noting that the two kinds of IPR are different, and therefore, interpretations of MPR based on these two kinds of IPR are different. PBS is a proxy measure of the patient price, while MSH is the procurement price of the buyer.
MPR
As a generally accepted criterion of MPR evaluation [25, 26] an MPR of 1 or less is interpreted as efficient procurement in the public sector, whereas an MPR below 3 is considered acceptable for the private sector. Although this criterion is suitable for evaluating procurement price, it is suitable as a reference when assessing patient price.
Affordability. Affordability of insulin and oral anti-diabetic medicines was assessed by two approaches. First, we used an approach recommended by HAI to assess affordability, which was expressed by the number of days' wages of the lowest-paid unskilled government worker (LPGW) required to purchase selected courses (usually 1 month for chronic disease) of treatment [20] . The dose required for 1-month treatment is calculated at 990 IU considering the average weight (about 60 kg) of Chinese adults [27] . The daily wage of lowest-paid unskilled government worker in Shaanxi is 6.82 US$, 2016 [28] . Second, as a supplement for the LPGW approach, we measured affordability of medicines using an impoverishment approach. This approach aims to calculate the proportion of households dropping below the poverty line after paying for some commodity (refers to medicine here), and it can be said to have been 'impoverished' by the payment. Details of this approach had been described in previous studies by Ni€ ens et al. [29, 30] . We made a line graph to portrait daily income of residents in Shaanxi [31] (Pre-Purchase Line (Pre-PL) in Figure 1 ) and another line representing the 1.9 US$ poverty line [32] (PL in Figure 1 ). Then we assumed that the whole population would purchase a medicine, which caused the subtraction of the daily income and generated a new income line graph (Post-Purchase Line (Post-PL) in Figure 1) . The intersection point (P1 in Figure 1 ) of Pre-PL and PL and the intersection point (P2 in Figure 1 ) of Post-PL and PL represent the percentage of impoverished population before and after purchasing the medicine respectively (P1 for percentage 1, P2 for percentage 2). The impoverishment rate is calculated thus:
prevalence of diabetes mellitus
We compared differences between prices between the two sectors by t-test for normally distributed data and by Wilcoxon rank test for non-normally distributed data. For all statistical analysis, a P value < 0.05 was considered as significant. All statistical analysis was implemented in SPSS 18.0.
Price components. Price components were recorded at five stages according to HAI Method [20] : manufacturer selling price (MSP), importer selling price, wholesaler selling price, outlet selling price and patients purchase price.
Results
In five public hospitals and 16 private outlets, a total of 28 insulin products were found 178 times (one time means any product was found in any outlet) during the survey. Most were packaged as a cartridge or prefilled pen (25 in 28 products) and only three products were injections in vials. About 75.3% were imported, 24.7% were produced locally, 47.8% were human insulin and 52.2% were insulin analogue.
Availability
Availability of insulin products was higher in public hospitals than private outlets. Availability (100%) of all three types of insulin was high in public hospitals and fairly high (>50%) in private outlets with the exception of human insulin (43%) ( Table 2) .
In contrast, availability of oral anti-diabetic medicines was higher in the private than the public sector. All oral anti-diabetic medicines had a high availability (>80%) if gliclazide 80 mg and gliclazide 30 mg were combined into one medicine for calculation. Availability of these medicines in the public sector was also high, with only glimepiride (availability = 60%) lower than 80%. Furthermore, availability of OBs of metformin 500 mg was higher than its LPGs counterpart in the public sector; this revealed that branded metformin, which is the most widely used medicine for diabetes, is highly likely to be prescribed in public hospitals.
Price and affordability
Compared with Australian PBS prices, only one kind of insulin product, namely prandial human insulin in the public sector, had a lower price. The price of most insulin products had an MPR > 1 and basal insulin analogue had the highest, that is, an MPR > 2. Prices in the public and private sectors were nearly equal, but for the three kinds of insulin products higher prices in public outlets were statistically significant (Prandial insulin analogue, P = 0.037; premixed human insulin, 0.025; and premixed insulin analogue, 0.007). In both sectors, the most expensive insulin product was basal insulin analogue (longacting insulin analogue), and the cheapest insulin was prandial human insulin (short-acting human insulin). We observed a higher price for insulin analogue than human insulin in all categories.
Compared to international reference prices from MSH, prices of all oral anti-diabetic medicines were higher, with an MPR ranging from 1.34 to 99.68. LPGs of gliclazide 80 mg had the lowest MPR of 1.34, which was considered acceptable for patients. By contrast, OBs of glimepiride had the highest MPR which was 99.68 times higher than MSH reference price. OBs always had a higher price than LPGs, and in the private sector their prices were slightly lower than in public, though the difference was not statistic significant (Table 3) .
According to HAI standard method, more than 1 day's wage of lowest-paid government worker (LPGW) is regarded as unaffordable. The result revealed that all kinds of insulin products were unaffordable. This result is consistent with analysis of insulin price; the most unaffordable insulin product was basal insulin analogue of which a 1-month course would cost more than 16 days' wage of LPGW (Table 4) .
In contrast, although OBs of oral anti-diabetic medicines are also unaffordable by the same criterion, most LPGs of oral anti-diabetic medicines cost about or less than 1 day's wage of LPGW except LPGs of acarbose.
The two approaches used to assess affordability of medicines in this study had similar results. The impoverishment approach calculates the number in the population that falls below poverty after purchasing a medicinal product. We can see from Table 4 that even the cheapest insulin product, prandial human insulin, would cause about 304 000 people in Shaanxi Province to drop below the World Bank poverty line [32] . Insulin analogue, especially the long-acting insulin analogue, would cause even more people to become impoverished. Of oral antidiabetic medicines, acarbose (both OBs and LPGs) and OBs of glimepiride also would cause high impoverishment rates ranging from 1.1% to 2.2% in Shaanxi.
Price components
Price components of insulin were collected at five stages: MSP, import tariff and importer markups, wholesaler markups, retailer markups and dispensing fee. In China, patients do not pay dispensing fees, so there is no OBs, original brands; LPGs, the lowest-priced generics (LPGs); "-" means that there is no original brand product for this dose.
contribution in the last stage. In this survey, Novolin R (prandial human insulin), Novolin 30R (premixed human insulin) and Novolin N (basal human insulin) were distributed by same wholesaler who applied the same markups and prices to these three Novolin products; therefore they were combined for analysis. We found that in the public sector the manufacturer's selling price or markup is the most important price component of insulin products, accounting for 60%-78% of insulin product costs as shown Figure 2 . Other important components in the public sector were import tariffs and taxes and retail markups of both imported and locally produced insulin products. From Figure 3 we learn that MSP comprises an even huger part of the insulin price in the private sector, accounting for 67% to 84%. Retail markups in the private sector were lower than in the public sector.
Discussion
This assessment of the availability, affordability and price components of insulin in China found that insulin products in Shaanxi have fairly high availability in public general hospitals, higher than in the private sector. But availability of oral anti-diabetic medicines was lower in public hospitals than private outlets. Compared with the findings of a preceding study in Hubei Province in central China, availability of insulin products in Shaanxi was higher in both public and private settings. There is also a higher availability of insulin products in Shaanxi than in other developing countries (where on average it is <60%) [33] . Whereas the availability of insulin products is high in Shaanxi, its affordability is very low: even the cheapest insulin would cause 304 000 people to become impoverished. These findings provide some base data on insulin availability and affordability in Shaanxi which may facilitate policy-making regarding diabetes control and aid future studies.
Availability
Availability of all the studied insulin products was high in public outlets. However, this conclusion had to be confined to general public hospitals (secondary and tertiary hospitals) because no public primary health institution was included in this study. Primary health institutions are the most convenient places to obtain health services for most diabetes patients, especially in rural areas. Nonetheless, this had little impact on our study because, according to a previous government survey [34] , these institutions rarely provide insulin products or consultation services on insulin medication. This situation is consistent with the findings that availability of insulin products was very low in Hubei, China. Patients have to attend higher-level health institutions such as tertiary hospitals for consultation and prescription of insulin. Given that most districts only have few large general hospitals, it would take a lot of time and money for patients to access services, due to overcrowding, longer waiting times to see a doctor and higher indirect costs for travel, accommodation and food.
Availability in private retail pharmacies was fairly high in Shaanxi, but the types of insulin they provided were not as heterogeneous as those stocked in public hospitals. This leaves few options for individualised therapy for diabetes mellitus (DM) patients, and reveals the need for private retail pharmacies to stock all three kinds and as many brands of insulin products as possible in order to provide a choice for patients. In comparison, all oral anti-diabetic medicines in this survey had a high OBs, original brands; LPGs, the lowest-priced generics (LPGs); NA, not available in this sector; -, there is no original brand product for this dose; **, there is no International Reference Price for this medicine or dose form.
availability in both public and private sectors, with a number of brands of each product available.
Price and affordability
Using the Australian PBS price as reference, all kinds of insulin were more expensive than in other developing countries [35] , but showing an opposite trend in Shaanxi in that insulin in the public sector was more expensive than in private sector. This may be explained by the price competition between public hospitals and private retail pharmacies: as outpatient is able to purchase insulin using basic medicine insurance funds in both sectors, private retail pharmacies may lower their prices to attract customers.
Since April 2017, all public hospitals in Shaanxi have cancelled markups of medicines; thus hospitals sell medicines to patients at the procurement price [36] .
Before the introduction of this policy, public hospitals levied 15% markups on the procurement price to patients. Currently, insulin products in public hospitals are cheaper than they were when we conducted this study.
Affordability of all insulin products was suboptimal in Shaanxi when assessed using the LPGW method. The limitation to this approach that some patients have a lower income than LPGW, especially in rural areas, which may overestimate affordability. We conducted another analysis on affordability of insulin products and oral medicines using the impoverishment approach, which also revealed poor affordability of insulin products. Even, the cheapest insulin would cause more than 400 000 patients to become impoverished in Shaanxi. We only considered affordability based on the direct cost of the medicines. This may underestimate the total cost as there is indirect cost involved in most cases such as travel, food and accommodation, loss of productivity and income. Also depending on the extent and severity of the disease, some patients may need more than one type of medication.
It seems that human insulin products have a better affordability than insulin analogue in all kinds of insulin. Studies have shown that analogue products have no significant clinical advantages over human insulin but are more expensive [37] . A study in Britain reports that if all insulin analogue products were substituted by therapeutically similar human insulin products, the financial burden on Britain's health system would be greatly reduced [38] . Short-acting human insulin and neutral protamine hagedorn (NPH) are included in China's National Essential Medicine List. These two kinds of insulin products should be stocked and prescribed more often in public hospitals to reduce the burden on patients.
The price of insulin in vials was much lower than for packaged in cartridges or prefilled pens, but vials have some disadvantages such as pain, difficult self-injection and wastage. Cartridges and prefilled pens are very convenient for patients to adjust dosage, and self-administration is easier and piercing pain is much less when using a cartridge. Therefore, insulin products in vials only comprise a small share of the insulin market in Shaanxi, and were even not found in the Hubei market [16] , although WHO recommends that it should be available in outlets [39] .
China has universal health coverage for almost all its population, but this public medicine insurance policy is more likely to reimburse inpatient cost and cost-intensive severe diseases like cancer. For chronic disease patients, the offset for outpatient medicine cost can be insufficient. We recommend three courses of action to help improve access to insulin products: increasing availability of insulin in public primary health institutions, especially for rural residents; enhancing reimbursements for outpatient chronic disease cost; and lowering the price of insulin products through negotiations with import suppliers.
Use of insulin
Suboptimal access to insulin products has physical and economic consequences on service delivery, and it has also hinders efforts to improve the quality of life of diabetic patients. Although we did not assess inappropriate use of insulin, there are reports that it does exist, which worsens the situation altogether. For instance, 56.1% of type 2 diabetes patients have negative attitudes towards insulin even when it is prescribed by physicians [40, 41] . Furthermore, 18% are unwilling to start insulin therapy because of fear of injections or concerns about addiction [40] , while some of those receiving the drug are using it inappropriately (in terms of dosage or self-administration). Future studies which focus on price, availability and rational use of insulin products will give a broader insight into the problem.
Limitations
First, we only chose three districts in Shaanxi Province, which is not representative of the whole province. But the chosen districts represent different economic development levels, which does portray the situation of availability, prices and affordability of insulin products in Shaanxi to some extent. Second, we did not include public primary hospitals, which may play an important role in diabetes patients' treatment and access to insulin. However, according to other similar studies, availability is quite poor in primary health institutions, and some primary health institutions do not even provide diabetes consultation services. Most patients in need of insulin products will have to go to general hospitals to consult physicians. Third, only five public hospitals were included in this study. The small sample size of public hospitals may lead to imprecise estimates of the availability of insulin in public hospitals. Fourth, we used the latest (2015) version of international reference price from MSH, which differs significantly from the previous versions; in evaluating 2016 prices this may have led to inaccuracies in our estimated prices. Finally, because of the impossibility to contact foreign insulin manufacturers, MSP was estimated from the wholesale procurement price and Chinese common tariff and tax rates.
Conclusion
Availability of insulin products in Shaanxi is high in public general hospitals and fairly high in private outlets. Availability of oral anti-diabetic medicines is high in both public and private settings. However, all insulin products and most OBs of oral anti-diabetic medicines are unaffordable. The poor affordability of insulin is a huge barrier for patients to control their condition and improve quality of life. The government should enhance availability and affordability of insulin through increasing reimbursement percentages, negotiation with suppliers and encouraging local production and market competition.
